[go: up one dir, main page]

DE60217532T8 - Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas - Google Patents

Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas Download PDF

Info

Publication number
DE60217532T8
DE60217532T8 DE60217532T DE60217532T DE60217532T8 DE 60217532 T8 DE60217532 T8 DE 60217532T8 DE 60217532 T DE60217532 T DE 60217532T DE 60217532 T DE60217532 T DE 60217532T DE 60217532 T8 DE60217532 T8 DE 60217532T8
Authority
DE
Germany
Prior art keywords
ultiplen
myelomas
treatment
carboline derivatives
ikb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE60217532T
Other languages
English (en)
Other versions
DE60217532D1 (de
DE60217532T2 (de
Inventor
Julian Brooklin ADAMS
Kenneth C Wellesley ANDERSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of DE60217532D1 publication Critical patent/DE60217532D1/de
Application granted granted Critical
Publication of DE60217532T2 publication Critical patent/DE60217532T2/de
Publication of DE60217532T8 publication Critical patent/DE60217532T8/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60217532T 2001-11-07 2002-11-06 Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas Active DE60217532T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34491101P 2001-11-07 2001-11-07
US344911P 2001-11-07
PCT/US2002/035645 WO2003039545A2 (en) 2001-11-07 2002-11-06 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers

Publications (3)

Publication Number Publication Date
DE60217532D1 DE60217532D1 (de) 2007-02-22
DE60217532T2 DE60217532T2 (de) 2007-10-31
DE60217532T8 true DE60217532T8 (de) 2008-02-07

Family

ID=23352621

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217532T Active DE60217532T8 (de) 2001-11-07 2002-11-06 Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas

Country Status (6)

Country Link
US (1) US9248124B2 (de)
EP (1) EP1443927B1 (de)
JP (2) JP4599501B2 (de)
AU (1) AU2002352498A1 (de)
DE (1) DE60217532T8 (de)
WO (1) WO2003039545A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248124B2 (en) * 2001-11-07 2016-02-02 Millennium Pharmaceuticals, Inc. Use of inhibitors of IκB kinase for the treatment of cancer
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
CA2521300A1 (en) * 2003-04-09 2004-10-28 Millennium Pharmaceuticals, Inc. Beta-carbolines useful for treating inflammatory disease
DE10326821A1 (de) * 2003-06-11 2005-01-05 Medical Enzymes Ag Pharmazeutische Kombinationspräparate zur Krebstherapie
EP2206713A1 (de) 2004-04-09 2010-07-14 Millennium Pharmaceuticals, Inc. Für die Behandlung von Entzündlichen Krankenheiten Nützliche beta-Carbolinen
CN100443178C (zh) 2006-03-10 2008-12-17 中国石油天然气股份有限公司 一种乙烯低聚的催化剂组合物及其应用
WO2007106884A2 (en) 2006-03-15 2007-09-20 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
CA2699461A1 (en) 2007-08-03 2009-02-12 The Regents Of The University Of California Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof
US20090131422A1 (en) * 2007-10-23 2009-05-21 Millennium Pharmaceuticals, Inc. Salts of an IKK inhibitor
WO2009054970A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Mesylate salt of an ikk inhibitor
WO2009151598A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
EP2161271A1 (de) * 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-Carbolin-Hemmer von NMP-ALK, RET und Bcr-Abl
WO2010099445A2 (en) * 2009-02-26 2010-09-02 Board Of Trustees Of Michigan State University Non-covalent inhibition of the 26s proteasome and uses thereof
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
FR2953837B1 (fr) * 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
EP3318563A1 (de) 2016-11-07 2018-05-09 Sanofi Substituierte pyrido[3,4-b]indole zur behandlung von knorpelerkrankungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2303627B (en) * 1995-07-26 1997-07-09 Arab Pharmaceutical Mfg Co Ltd Anti-tumour platinum-harmine complex
JP2001515871A (ja) * 1997-09-10 2001-09-25 ユーエイビー リサーチ ファンデーション 骨芽細胞性幹細胞因子を阻害することによる破骨細胞形成の制御
JPH11180873A (ja) * 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
DE19807993A1 (de) * 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001068648A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
MEP28108A (en) * 2000-03-15 2010-10-10 Sanofi Aventis Deutschland Substituted beta-carbolines with ikb-kinase inhibiting activity
US9248124B2 (en) * 2001-11-07 2016-02-02 Millennium Pharmaceuticals, Inc. Use of inhibitors of IκB kinase for the treatment of cancer

Also Published As

Publication number Publication date
US9248124B2 (en) 2016-02-02
WO2003039545A3 (en) 2003-10-30
DE60217532D1 (de) 2007-02-22
US20050049265A1 (en) 2005-03-03
EP1443927A2 (de) 2004-08-11
JP2010031061A (ja) 2010-02-12
JP4599501B2 (ja) 2010-12-15
EP1443927B1 (de) 2007-01-10
WO2003039545A2 (en) 2003-05-15
HK1069311A1 (en) 2005-05-20
DE60217532T2 (de) 2007-10-31
JP2005529842A (ja) 2005-10-06
AU2002352498A1 (en) 2003-05-19

Similar Documents

Publication Publication Date Title
DE60217532T8 (de) Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
DE502004008604D1 (de) Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
DE602004020793D1 (de) 5-phenyl-4-methyl-thiazol-2-yl-amin-derivate als inhibitoren von phosphatidylinositol-3-kinase-enzymen (pi3) zur behandlung entzündlicher erkrankungen der luftwege
DE60327438D1 (de) Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
CY2015003I2 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
ATE331512T1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
ATE557021T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
AU2002338807A1 (en) Use of c-kit inhibitors for the treatment of myeloma
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
EP1556085A4 (de) Verbindungen zur behandlung von stoffwechselst rungen
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
DE60325855D1 (de) Rifampicin zur Behandlung der Angiogenese
ATE430577T1 (de) Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
AU2003205452A8 (en) Bmp inhibitors for the treatment of spondyloarthropathies
DE602004003831D1 (de) 2-ä4-(2-hydroxymethyl-phenylamino)-piperidin-1-ylü-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
ATE448228T1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne

Legal Events

Date Code Title Description
8364 No opposition during term of opposition